Literature DB >> 9768525

Idiopathic bile acid malabsorption: qualitative and quantitative clinical features and response to cholestyramine.

L Sinha1, R Liston, H J Testa, K J Moriarty.   

Abstract

BACKGROUND: Idiopathic bile acid malabsorption is a poorly recognized cause of chronic diarrhoea. The SeHCAT (75Selenium HomotauroCholic Acid Test) can accurately diagnose this condition. AIM: To identify patients with idiopathic bile acid malabsorption, to describe their clinical features, both qualitatively and quantitatively, and to assess the response to cholestyramine.
METHOD: Idiopathic bile acid malabsorption was considered in all patients complaining of chronic diarrhoea. They were included in the study if their SeHCATs were positive (< 15% retention) and secondary causes of bile acid malabsorption were excluded. The response to therapy with cholestyramine was assessed.
RESULTS: Nine patients were diagnosed with idiopathic bile acid malabsorption (median SeHCAT retention 8%, range 3-12.6). Their median daily faecal weight was 285 g (range 85-676) and median faecal fat output was 17 mmol/24 h (range 8.3-38.8). Six patients had an immediate response to cholestyramine. There was a marked reduction in stool frequency (median stool frequency pre-treatment 5/day vs. 2/day post-treatment, P = 0.03). Five patients had large volume diarrhoea (faecal weight > 200 g/day) and three had steatorrhoea.
CONCLUSIONS: Idiopathic bile acid malabsorption, once suspected, especially by documenting true 'large volume' watery diarrhoea or steatorrhoea, is easily diagnosed and response to therapy is often very good. There is often a previous history of gastrointestinal infection and this condition should be considered in patients with chronic diarrhoea of undetermined origin, especially before they are labelled as having irritable bowel syndrome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9768525     DOI: 10.1046/j.1365-2036.1998.00388.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  20 in total

1.  Managing bile acid diarrhoea.

Authors:  Julian R F Walters; Sanjeev S Pattni
Journal:  Therap Adv Gastroenterol       Date:  2010-11       Impact factor: 4.409

2.  Chronic diarrhoea.

Authors:  R Spiller
Journal:  Gut       Date:  2007-12       Impact factor: 23.059

3.  Do the Symptom-Based, Rome Criteria of Irritable Bowel Syndrome Lead to Better Diagnosis and Treatment Outcomes? The Con Argument.

Authors:  Michael Camilleri
Journal:  Clin Gastroenterol Hepatol       Date:  2009-10-20       Impact factor: 11.382

Review 4.  Use and indications of cholestyramine and bile acid sequestrants.

Authors:  Franco Scaldaferri; Marco Pizzoferrato; Francesca Romana Ponziani; Giovanni Gasbarrini; Antonio Gasbarrini
Journal:  Intern Emerg Med       Date:  2011-07-08       Impact factor: 3.397

Review 5.  Short bowel syndrome in the NICU.

Authors:  Sachin C Amin; Cleo Pappas; Hari Iyengar; Akhil Maheshwari
Journal:  Clin Perinatol       Date:  2013-01-17       Impact factor: 3.430

6.  Bile acid malabsorption in microscopic colitis and in previously unexplained functional chronic diarrhea.

Authors:  F Fernandez-Bañares; M Esteve; A Salas; T M Forné; J C Espinos; J Martín-Comin; J M Viver
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

Review 7.  Irritable bowel syndrome: a clinical review.

Authors:  Rosa L S Soares
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 8.  New insights into bile acid malabsorption.

Authors:  Ian Johnston; Jonathan Nolan; Sanjeev S Pattni; Julian R F Walters
Journal:  Curr Gastroenterol Rep       Date:  2011-10

Review 9.  Review article: new receptor targets for medical therapy in irritable bowel syndrome.

Authors:  M Camilleri
Journal:  Aliment Pharmacol Ther       Date:  2010-01       Impact factor: 8.171

Review 10.  Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment.

Authors:  Alan N Barkun; Jonathan Love; Michael Gould; Henryk Pluta; Hillary Steinhart
Journal:  Can J Gastroenterol       Date:  2013-11       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.